Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder


Clinical impact ratings GP/FP/Primary care ★★☆☆☆☆ Mental health ★★★★★★★ Psychiatry ★★★★★★★ Paediatrics ★★★★★★★

In adolescents with major depressive disorder (MDD), how do fluoxetine, cognitive behavioural therapy (CBT), and their combination compare for effectiveness?

**Conclusions**

In adolescents with major depressive disorder, fluoxetine plus cognitive behavioural therapy was most effective.

*Calculated from data in article.

A modified version of this abstract appears in Evidence-Based Nursing.

**Commentary**

TADS was published during a time of great controversy in the treatment of adolescent depression. Much previous research in this field, both published and unpublished, has been heavily criticised, and the safety and effectiveness of SSRIs is currently under close scrutiny, particularly with regard to suicidality. To date, TADS represents the largest treatment trial of adolescent depression and addresses some of the criticisms of earlier studies. TADS was a non-industry funded study, with predetermined measures of adverse events and relatively few exclusion criteria. It was also the first published study to directly compare CBT with antidepressant medication. The main finding was that combined treatment with CBT and fluoxetine had a greater effect on depressive symptoms than either treatment alone or placebo. However, these results are complicated by the fact that fluoxetine treated patients had an overall increased risk of “harm related” and other adverse events, and an excess of suicide attempts (although the numbers were too small to reach conventional statistical significance [7 in total]). CBT alone was not effective, although previous studies have shown it to be the treatment of choice in less depressed samples.

How should the results of TADS influence clinician’s treatment of adolescents with moderate to severe depression? Combined treatment appears to be most beneficial; however, CBT is not always readily available, and also we do not yet have information about its cost effectiveness. Despite recent concerns, fluoxetine is still the next treatment available, and also we do not yet have information about its cost effectiveness. CBT with antidepressant medication. The main finding was that combined treatment with CBT and fluoxetine had a greater effect on depressive symptoms than either treatment alone or placebo. However, these results are complicated by the fact that fluoxetine treated patients had an overall increased risk of “harm related” and other adverse events, and an excess of suicide attempts (although the numbers were too small to reach conventional statistical significance [7 in total]). CBT alone was not effective, although previous studies have shown it to be the treatment of choice in less depressed samples.

**Main Results**

Combined treatment with fluoxetine plus CBT led to greater improvement in CDRS–R scores than did placebo ((mean difference 10.8, p = 0.001), fluoxetine alone ((mean difference 4.4, p = 0.02), or CBT alone (mean difference 9.4, p = 0.001). Fluoxetine plus CBT also reduced suicidal thoughts. Fluoxetine plus CBT and fluoxetine had greater CGI-I response rates relative to placebo and CBT alone. Numbers needed to treat were 3 (95% CI 2 to 4) for fluoxetine plus CBT and 4 (CI 3 to 8) for fluoxetine alone relative to placebo. The 2 fluoxetine groups had more harm related events than the CBT alone and placebo groups (p = 0.04) (table).

For correspondence: Dr J S March, Duke University Medical Center, Durham, NC, USA. jmarch@acpub.duke.edu

Sources of funding: National Institute of Mental Health; fluoxetine and placebo provided by Lilly Inc.

### Fluoxetine or fluoxetine plus cognitive behavioural therapy (CBT) v placebo or CBT alone for major depressive disorder in adolescents*

<table>
<thead>
<tr>
<th>Outcome at 12 weeks</th>
<th>Event rates</th>
<th>NNH (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harm related adverse events</td>
<td>10% v 4.9%</td>
<td>10% (2.8 to 292) (97 to 713)</td>
</tr>
</tbody>
</table>

*Abbreviations defined in glossary; RRI, NNH, and CI calculated using odds ratio in article.
Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder

*Evid Based Med* 2005 10: 46
doi: 10.1136/ebm.10.2.46

Updated information and services can be found at:
http://ebm.bmj.com/content/10/2/46

These include:

References
This article cites 2 articles, 1 of which you can access for free at:
http://ebm.bmj.com/content/10/2/46#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Child and adolescent psychiatry (159)
- Mood disorders (including depression) (97)
- Clinical trials (epidemiology) (1594)
- Drugs: musculoskeletal and joint diseases (349)
- Drugs: CNS (not psychiatric) (262)
- Drugs: psychiatry (59)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/